Group 1 - The company's total revenue for the six months ending June 30, 2025, increased by 1.3% to RMB 209.2 million from RMB 206.4 million in the same period of 2024, primarily driven by sales of the commercialized drug Envita (a subcutaneous PD-L1 inhibitor) [1] - Gross profit for the same period rose by 2.1% to RMB 192.9 million from RMB 188.9 million in 2024, with a gross margin increase from 91.5% to 92.2%, attributed to higher product sales and a slight reduction in related taxes and fees [1] - The total comprehensive loss decreased by RMB 21.5 million to RMB 92.6 million for the six months ending June 30, 2025, due to increased gross profit from sales growth and effective control of administrative expenses, which saved RMB 13.8 million [1] Group 2 - The company holds a broad patent portfolio, including 13 authorized patents in China, 24 authorized patents in other jurisdictions, and 19 pending patent applications, demonstrating its commitment to protecting its products and technologies [2] - As an innovative, commercialization-driven biopharmaceutical company, the company has made significant breakthroughs in various fields, with ongoing clinical research and development efforts focused on early-stage research and expanding indications for Envita [2] - The company aims to maintain stable revenue while achieving all key R&D milestones as planned, emphasizing its pursuit of breakthrough innovations and deepening global strategic partnerships to advance overseas commercialization [2]